1、How Artificial Intelligence isReshaping Drug DevelopmentExecutive SummaryIn the challenging landscape of drug development,where bringing a medication to market hasgotten slower and costlier over time,artificial intelligence(AI)solutions are gaining traction.Thisissue,coupled with escalating public a

2、nd political calls for more affordable medications,hasprompted a surge in AI-based initiatives aimed at reducing costs and expediting developmenttimelines.Additional momentum behind AI adoption in drug development is being fueled byadvancements in AI technology,heightened awareness,and improved comp

3、uter processingspeed.Estimates point to a substantial total addressable market of around$50 billion for AI-enableddrug development,with the expectation that 30%of new drugs will be discovered using AI by2025.Notably,the field is witnessing a proliferation of players,categorized into biopharmacompani

4、es with a robust AI focus and providers of AI tools working in tandem with largebiopharma players.Meanwhile,collaboration is on the rise with big tech companies like Nvidia,Alphabet and Amazon.In clinical trials,AI-derived drug candidates are gaining traction,while future AI applications areexpected

5、 to expand into challenging areas such as biologics,oncology,and rare diseases.Experts are enthusiastic about the big picture while acknowledging that AI-based drugdevelopment is still in an early and uncertain stage,and offered varied opinions on its progressand challenges.Lets explore this topic a

6、nd the key industry debates by leveraging AlphaSense,including first-person insights from our expert transcript library.A Ripe Time for AI SolutionsDrug development is an exceedingly time-consuming and expensive process.On average,ittakes more than 12 years and$1.3 billion to bring just one drug to